SRPT

Sarepta Therapeutics, Inc. Press Releases

$13.07
*  
0.07
0.54%
Get SRPT Alerts
*Delayed - data as of Mar. 26, 2015  -  Find a broker to begin trading SRPT now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    SRPT Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By













Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients
1/14/2015 8:30:00 AM - Business Wire
▲12.67 % Price Change since this news event. The Volume Ratio is 0.53.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy
1/12/2015 7:00:00 AM - Business Wire
▼-6.64 % Price Change since this news event. The Volume Ratio is 4.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
1/7/2015 10:47:00 AM - Business Wire
▼-10.60 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day